Vaccine Poliomyelitis Oral Bivalen Type 1 & 3

DESCRIPTION
The live types 1 & 3 oral polio vaccine (bOPV) is a bivalent vaccine containing suspension of types 1 & 3 attenuated Polio viruses (Sabin strains), prepared in primary monkey kidney cell. Each dose (2 drops = 0.1 mL) contains not less than 106.0 infective units of type 1 and 105.8 of type 3. Sucrose is used as stabilizer. bOPV may contain trace amounts of not more than 2 mcg Erythromycin and not more than 10 mcg Kanamycin.

ADMINISTRATION

  • bOPV must only be administered orally. Two drops are delivered directly into the mouth from the multidose vial by dropper. Care should be taken not to contaminate a multidose dropper with saliva of the vaccinee.
  • Once opened, multi-dose vials should be kept between +2°C to +8°C.
  • Multi-dose  vials  of  bOPV  from  which one or more doses of vaccine have been removed during an immunization session may be used in subsequent immunization session for up to a maximum of 4 weeks, provided that all of following conditions are met (as described in the WHO policy statement: The use of opened multi-dose vials in subsequent immunization sessions. WHO/V&B/00.09), see page 83.

IMMUNIZATION SCHEDULE

Bivalent Types 1 & 3 Polio Vaccine is indicated for Poliomyelitis Suplementary Immunization Activities (SIAs) in children from 0 to 5 years of age, to interrupt types 1 & 3 polio virus transmission in remaining polio endemic areas. The routine poliomyelitis vaccination program should continue to use trivalent vaccines according to national policy.

IMMUNIZATION SCHEDULE

Bivalent Types 1 & 3 Polio Vaccine is indicated for Poliomyelitis Suplementary Immunization Activities (SIAs) in children from 0 to 5 years of age, to interrupt types 1 & 3 polio virus transmission in remaining polio endemic areas. The routine poliomyelitis vaccination program should continue to use trivalent vaccines according to national policy.

PRESENTATION
The vaccine comes in vials of 20 doses.

 

SIDE EFFECTS

  • In the vast majority of cases there are no side effects reported with the trivalent OPV that includes the same bOPV component. Very rarely, there may be vaccine-associated paralysis.
  • Persons in close contact with a recently vaccinated child may very rarely be at risk of vaccine-associated paralytic poliomyelitis.

SPECIAL WARNINGS & PRECAUTIONS FOR USE

In case of diarrhea, the dose received will not be counted as part of the immunization schedule and it should be repeated after recovery. bOPV should  not to be used for routine immunization.

CONTRAINDICATIONS Immune deficiency

  • Individuals infected with human immunodeficiency virus (HIV), both asymptomatic and symptomatic, should be immunized with bOPV according to standard schedules.
  • However, the vaccine is contraindicated in those with primary immune deficiency disease or suppressed immune response from medication, leukaemia, lymphoma, or generalized malignancy.

STORAGE

  • Vaccine is potent if stored not higher than -20°C until the expiry date indicated on label of the vial.
  • It  can  be  stored  for  up  to  six  months between +2°C to +8°C.
  • The vaccine may present a colour varying from light yellow to light red, due to a slight variation of pH, however this does not affect the quality of the vaccine.